BDSX · Biodesix Inc
Market Cap
$253.81M
Shares
10.55M
Volume · Oct 21
54.22K
Avg daily vol (3M)
99.55K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.93
Open$24.07
Day$23.66–24.55
52W close$5.46–30.60
Avg vol 30d90K
Short int202K · 1.9% float · 1.8d
Short vol29%
Last earningsAug 5, 2026
DataOct 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 2 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$102.94M
Trailing 12 months
Net income (TTM)
−$27.76M
Trailing 12 months
Revenue growth YoY
+34.2%
Year over year
Operating margin
-20.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$20.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+40.4%
Year over year · more shares
Price change (1Y)
+250.4%
Trailing year
Short interest
1.9%
Latest settlement · 1.8 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Biodesix delivered 34% Q2 revenue growth to $26.9M, 42% diagnostic testing growth, 82% gross margins (+200 bps YoY), and a 56% Adjusted EBITDA loss improvement, while reiterating full-year 2026 revenue guidance of $108–114M (midpoint ~25% growth). Development Services revenue declined year-over-year, and management cautioned that further gross margin upside is limited and biopharma services revenue is lumpy.
Bullish
- + Q2 revenue grew 34% YoY to $26.9M, with Diagnostic Testing up 42% on 38% volume growth
- + Gross margin reached 82%, a 200 bps YoY improvement, marking a fifth consecutive quarter at or above 80%
- + Net loss improved 37% YoY to $7.3M and cash burn (ex-ATM) improved 70% to $2.1M, with $30M cash on hand
- + Reiterated previously raised full-year 2026 revenue guidance of $108–114M, midpoint ~25% growth, with continued Adjusted EBITDA progress expected
Bearish
- − Development Services revenue declined to $1.5M from $2.1M YoY due to project timing
- − Management indicated limited further gross margin upside beyond the ~80% range
- − Management cautioned that biopharma/Development Services revenue can be seasonal and lumpy, creating execution risk against guidance
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
−10%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
73%
mid-range
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+118%
trailing
YTD return
+252%
this year
Relative strength
+110%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $18 — 50d above 200d
Institutional flow
Distributing
3 of 45 funds reported for Sep 30 · net -7.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.91% of float · ▼ -5.7% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
45 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Revenue growth
+24%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-23.5M
Balance sheet
$31.0M
net debt
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 5, 2026
Full-year revenue
· full year 2026
Maintained
$108M – $114M
May 4, 2026
$108M – $114M
changed to
Aug 5, 2026
$108M – $114M
prior FY $88.5M
midpoint +25.4% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Nov 3, 2025
Revenue
· full year 2025
$84M – $86M
Guided vs delivered
· last 4 settled
Revenue
full year 2025
guided $84M – $86M
$88.5M
Beat +4.1%
Total revenue
full year 2024
guided $70M – $72M
$71.32M
In line
Total revenue
2023
guided $50M – $52M
$49.09M
Miss −3.8%
Total revenue
2022
guided $37.5M – $39.5M
$38.21M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
−10%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
73%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $27 › 200d $18 — 50d above 200d
Institutional flow
Distributing
3 of 45 funds reported for Sep 30 · net -7.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.91% of float · ▼ -5.7% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
45 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $24 · 73%
Range high $31
vs 200-day avg +32%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 3.2M | second quarter 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -7.27M
+1.98M Interest expense
+1.39M Depreciation and amortization
+820K Share-based compensation expense
+0K Change in fair value of warrant liability, net
-97K Other (income) expense, net
= Adjusted EBITDA -3.18M
|
|||
| Development Services revenue | 1.5M | second quarter 2026 | — |
| Diagnostic Testing revenue | 25.4M | second quarter 2026 | — |
| Gross margin | 82% | second quarter 2026 | — |
| Operating expenses (excluding direct costs and expenses) | 27.4M | second quarter 2026 | — |
| Stock compensation expense | 0.8M | second quarter 2026 | — |
| test volumes | 20,900 | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDSX
this stock
Biodesix Inc
|
$253.81M | +251.9% | +24.1% | — | 1.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$258.56B | +19.8% | +14.5% | 37.6 | 1.5% |
|
DHR
Danaher Corp
|
$164.40B | +2.2% | +8.5% | 38.2 | 1.3% |
|
NTRA
Natera, Inc.
|
$59.59B | +80.4% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$50.00B | +30.6% | +6.4% | 34.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDSX | -0.3% | -18.3% | +117.9% | -19.8% | +251.9% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -0.7% | -19.0% | +110.4% | -21.2% | +238.5% |